Showing 911-920 of 10032 results for "".
Had Your Fill?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/had-your-fill/18531/If the US filler market seems robust, you should see what's available outside the US, says Hassan Galadari, MD. He provides a global perspective on fillers with a focus on up-and-coming products, the importance of understanding anatomy, and advances in recognizing and treating complications.Pearls from NYC: Oy Vey!
https://practicaldermatology.com/topics/skin-cancer-photoprotection/pearls-from-nyc-oy-vey-/18752/By Gary Goldenberg, MD and Seemal R. Desai, MDWhat happens if you shave a melanoma? Dr. Goldenberg addresses a common question from the clinic. The good news? The type of biopsy done does not appear to affect long-term survival in melanoma.Getting the Upper Hand on NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/getting-the-upper-hand-on-nmsc/18758/By Seemal R. Desai, MD and Anthony Rossi, MDDecide what type of treatment to use to treat the specific, biopsy-confirmed presentation, says Dr. Rossi. He shares tips to optimize topical treatment outcomes in non-melanoma skin cancer.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availThe Evolving Paradigm in Treatment of Psoriasis
https://practicaldermatology.com/topics/psoriasis/the-evolving-paradigm-in-treatment-of-psoriasis/18640/Bruce Strober, MD, reviews the latest science in the management of psoriasis. Treatment strategies on the horizon may offer significantly improved efficacy with attractive dosing schedules, adding to the ability to help patients manage difficult skin and systemic implications of psoriasis, he said.Balneotherapy Continued: A Future in US Dermatology?
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/balneotherapy-continued-a-future-in-us-dermatology/54116/Practical Dermatology editorial board member Peter Lio, MD, and Karan Lal, DO, MS, FAAD, continue their discussion of the International Journal of Biometeorology article “Balneotherapy using thermal mineral water baths and dermatological diseases: a systematic review,” covering the evidence supportiEstrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaAn Update on Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/an-update-on-neuromodulators-and-fillers/19983/Suneel Chilukuri, MD discusses daxibotulinumtoxinA and its potential for longer lasting results. He also reviews newly available fillers and specific options for various areas of the face. Plus, he talks about low-cost options and how he’s using devices like SkinPen.Scientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, Re